SI2217205T1 - Farmacevtske sestave na podlagi superstruktur zaviralca/blokatorja angiotenzinskih receptorjev (arb) in inhibitorja nevtralne endopeptidaze (nep) - Google Patents

Farmacevtske sestave na podlagi superstruktur zaviralca/blokatorja angiotenzinskih receptorjev (arb) in inhibitorja nevtralne endopeptidaze (nep)

Info

Publication number
SI2217205T1
SI2217205T1 SI200831427T SI200831427T SI2217205T1 SI 2217205 T1 SI2217205 T1 SI 2217205T1 SI 200831427 T SI200831427 T SI 200831427T SI 200831427 T SI200831427 T SI 200831427T SI 2217205 T1 SI2217205 T1 SI 2217205T1
Authority
SI
Slovenia
Prior art keywords
superstructures
arb
nep
blocker
inhibitor
Prior art date
Application number
SI200831427T
Other languages
English (en)
Inventor
Suliman Al-Fayoumi
Jiahui Hu
Natrajan Kumaraperumal
Alan Edward Royce
Colleen Ruegger
Erika Aina Zannou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2217205(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2217205T1 publication Critical patent/SI2217205T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
SI200831427T 2007-11-06 2008-11-04 Farmacevtske sestave na podlagi superstruktur zaviralca/blokatorja angiotenzinskih receptorjev (arb) in inhibitorja nevtralne endopeptidaze (nep) SI2217205T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06
PCT/US2008/082324 WO2009061713A1 (en) 2007-11-06 2008-11-04 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
EP08848154.4A EP2217205B1 (en) 2007-11-06 2008-11-04 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor

Publications (1)

Publication Number Publication Date
SI2217205T1 true SI2217205T1 (sl) 2015-10-30

Family

ID=40451030

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200831427T SI2217205T1 (sl) 2007-11-06 2008-11-04 Farmacevtske sestave na podlagi superstruktur zaviralca/blokatorja angiotenzinskih receptorjev (arb) in inhibitorja nevtralne endopeptidaze (nep)
SI200832204T SI3067043T1 (sl) 2007-11-06 2008-11-04 Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
SI200831654A SI2295035T1 (sl) 2007-11-06 2008-11-04 Dvojno delujoči farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (arb) in inhibitorja nevtralne endopeptidaze (nep)

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200832204T SI3067043T1 (sl) 2007-11-06 2008-11-04 Farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (ARB) in zaviralca nevtralne endopeptidaze (NEP)
SI200831654A SI2295035T1 (sl) 2007-11-06 2008-11-04 Dvojno delujoči farmacevtski sestavki na osnovi superstruktur antagonista/blokatorja angiotenzinskega receptorja (arb) in inhibitorja nevtralne endopeptidaze (nep)

Country Status (34)

Country Link
US (3) US20100267786A1 (sl)
EP (4) EP4186491A1 (sl)
JP (2) JP5653218B2 (sl)
KR (2) KR101700062B1 (sl)
CN (2) CN101848700A (sl)
AR (1) AR069184A1 (sl)
AU (1) AU2008324878B2 (sl)
BR (1) BRPI0823505A2 (sl)
CA (1) CA2703598C (sl)
CL (1) CL2008003298A1 (sl)
CY (2) CY1116280T1 (sl)
DK (3) DK2217205T3 (sl)
EC (1) ECSP10010160A (sl)
ES (3) ES2587336T3 (sl)
FI (1) FI3067043T3 (sl)
GT (1) GT201000131A (sl)
HK (3) HK1149721A1 (sl)
HR (3) HRP20230178T3 (sl)
HU (2) HUE028866T2 (sl)
IL (3) IL262990B2 (sl)
JO (1) JOP20080499B1 (sl)
MA (1) MA31797B1 (sl)
MX (1) MX2010004930A (sl)
MY (1) MY153730A (sl)
NZ (1) NZ584686A (sl)
PE (2) PE20141072A1 (sl)
PL (3) PL3067043T3 (sl)
PT (3) PT2217205E (sl)
RU (1) RU2493844C3 (sl)
SG (1) SG185951A1 (sl)
SI (3) SI2217205T1 (sl)
TN (1) TN2010000200A1 (sl)
TW (1) TWI484982B (sl)
WO (1) WO2009061713A1 (sl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3067043T3 (fi) 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia
JP5466759B2 (ja) 2009-05-28 2014-04-09 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
CN103896796B (zh) 2009-05-28 2016-04-27 诺华股份有限公司 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
ES2702529T3 (es) 2010-08-24 2019-03-01 Novartis Ag Una composición farmacéutica para uso en la prevención o tratamiento de la insuficiencia cardíaca en un mamífero que recibe terapia anticoagulante
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2882771C (en) 2012-08-24 2021-02-23 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
NZ710574A (en) 2013-02-14 2017-11-24 Novartis Ag Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
PL3626270T3 (pl) 2013-08-26 2024-04-08 Novartis Ag Leczenie chorób sercowo-naczyniowych
US20160206597A1 (en) 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
EP3443960A1 (en) 2014-12-08 2019-02-20 Crystal Pharmatech Co., Ltd. Crystalline form of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
PT3294283T (pt) 2015-05-11 2023-06-07 Novartis Ag Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
EP3302460A1 (en) 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106397249A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种高稳定性lcz696结晶粉末及其制备方法
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
US10722471B2 (en) 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
CN108601741B (zh) 2016-02-03 2022-05-24 诺华股份有限公司 有机化合物的盖伦制剂
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
ES2890573T3 (es) * 2017-03-31 2022-01-20 Tiefenbacher Alfred E Gmbh & Co Kg Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) * 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
PL3658122T3 (pl) 2017-07-28 2021-10-18 Synthon B.V. Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
WO2019246503A1 (en) 2018-06-22 2019-12-26 Ideaz, Llc Diphenyl tablets and methods of preparing the same
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607355A (en) 1898-07-12 Carrier for bicycles
US607893A (en) 1898-07-26 Automatic switch-operating machine
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
JP4880118B2 (ja) * 1997-11-17 2012-02-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
CA2415962C (en) 2000-07-19 2010-07-06 Novartis Ag Valsartan salts
RU2334513C3 (ru) 2002-01-17 2017-10-24 Новартис Аг Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
AU2003223637A1 (en) 2002-04-15 2003-11-03 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2519490A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd Polymorphis of valsartan
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
WO2007049292A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
WO2007052307A2 (en) 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
EP2260755B1 (en) 2005-11-07 2013-12-25 Stryker Corporation Patient handling device including normal condition lamp
JP2009514961A (ja) 2005-11-08 2009-04-09 ノバルティス アクチエンゲゼルシャフト アンギオテンシンｉｉ受容体ブロッカー、カルシウムチャネルブロッカーおよび他の活性剤の組合せ
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
FI3067043T3 (fi) 2007-11-06 2023-03-18 Novartis Ag Angiotensiinireseptoriantagonistin/-salpaajan (arb) ja neutraalin endopeptidaasin (nep) estäjän superrakenteisiin perustuvia farmaseuttisia koostumuksia

Also Published As

Publication number Publication date
KR101589317B1 (ko) 2016-01-28
CA2703598C (en) 2016-08-09
ES2587336T3 (es) 2016-10-24
EP3067043A1 (en) 2016-09-14
PT2217205E (pt) 2015-06-08
PL2217205T3 (pl) 2015-07-31
DK3067043T3 (da) 2023-02-27
RU2010123027A (ru) 2011-12-20
DK2217205T3 (en) 2015-05-11
HRP20150459T1 (hr) 2015-07-17
TWI484982B (zh) 2015-05-21
PT3067043T (pt) 2023-03-01
PL2295035T3 (pl) 2016-11-30
EP2295035B1 (en) 2016-05-18
US20210085631A1 (en) 2021-03-25
KR101700062B9 (ko) 2022-11-23
CL2008003298A1 (es) 2009-06-26
CY1116280T1 (el) 2017-03-15
PE20091390A1 (es) 2009-10-13
JP2015038069A (ja) 2015-02-26
MX2010004930A (es) 2010-05-27
FI3067043T3 (fi) 2023-03-18
EP2217205A1 (en) 2010-08-18
HRP20230178T3 (hr) 2023-03-31
NZ584686A (en) 2013-03-28
EP2295035A2 (en) 2011-03-16
AU2008324878B2 (en) 2013-04-18
KR20100085087A (ko) 2010-07-28
EP2217205B1 (en) 2015-03-04
EP3067043B1 (en) 2022-11-30
JP2011503082A (ja) 2011-01-27
CA2703598A1 (en) 2009-05-14
GT201000131A (es) 2012-04-30
IL205208A (en) 2017-01-31
IL205208A0 (en) 2010-12-30
ES2536514T3 (es) 2015-05-26
DK2295035T3 (en) 2016-08-29
ES2939163T3 (es) 2023-04-19
ECSP10010160A (es) 2010-06-29
RU2493844C2 (ru) 2013-09-27
EP2295035A3 (en) 2012-08-08
PT2295035T (pt) 2016-08-22
HK1143529A1 (en) 2011-01-07
US20100267786A1 (en) 2010-10-21
IL262990B1 (en) 2023-06-01
SI3067043T1 (sl) 2023-04-28
AU2008324878A1 (en) 2009-05-14
AR069184A1 (es) 2010-01-06
MA31797B1 (fr) 2010-10-01
IL249922A0 (en) 2017-03-30
TN2010000200A1 (en) 2011-11-11
CY1117883T1 (el) 2017-05-17
HUE061321T2 (hu) 2023-06-28
SI2295035T1 (sl) 2016-09-30
KR20150139624A (ko) 2015-12-11
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
JOP20080499B1 (ar) 2022-09-15
CN101848700A (zh) 2010-09-29
PL3067043T3 (pl) 2023-05-08
IL262990B2 (en) 2023-10-01
WO2009061713A1 (en) 2009-05-14
HK1149721A1 (zh) 2011-10-14
PE20141072A1 (es) 2014-09-10
EP4186491A1 (en) 2023-05-31
SG185951A1 (en) 2012-12-28
CN103251587A (zh) 2013-08-21
HK1224195A1 (zh) 2017-08-18
IL262990A (en) 2018-12-31
HRP20160988T1 (hr) 2016-10-07
JP5653218B2 (ja) 2015-01-14
KR101700062B1 (ko) 2017-01-26
HUE028866T2 (en) 2017-01-30
BRPI0823505A2 (pt) 2015-06-16
MY153730A (en) 2015-03-13
TW200936183A (en) 2009-09-01
KR101589317B9 (ko) 2022-11-23

Similar Documents

Publication Publication Date Title
IL262990A (en) Dual-activity pharmaceutical compositions based on angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor superstructures
HUS2100003I1 (hu) Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja
IL194642A0 (en) Antagonist anti-cd40 antibody pharmaceutical compositions
IL197788A0 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2046887A4 (en) Light-Crosslinkable Polyolefin Compositions
HK1133597A1 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
ITMI20062230A1 (it) Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
ZA200704717B (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor
GB0619891D0 (en) Pharmaceutical composition of risedronate
ZA200901001B (en) Antiretroviral solid oral composition
ZA200902164B (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor